New Tool for Mining Bacterial Genome for Novel Drugs Jan.

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone

New Tool for Mining Bacterial Genome for Novel Drugs

Jan. 25, 2013 — Vanderbilt biochemists have discovered that the process bacteria undergo when they become drug resistant can act as a powerful tool for drug discovery.

The structure of two of the drug-like molecules discovered by triggering Nocardius' drug-resistant response.

Their findings -- reported this week in the Online Early Edition of the Proceedings of the National Academy of Sciences -- should give a major boost to natural products drug discovery -- the process of finding new drugs from compounds isolated from living organisms -- by substantially increasing the number of novel compounds that scientists can extract from individual microorganisms.

Bacteria have traditionally been the source of important drugs such as antibiotics and anticancer agents. Researchers looking for new bacterially synthesized drugs have long known that bacterial genomes contain a large number of "silent genes" that contain the instructions for making drug-like compounds. But, until now, scientists have found it is very difficult to find ways to turn on the production of these compounds, known as secondary metabolites.

While investigating how bacteria develop drug resistance, Vanderbilt biochemists Brian Bachmann and John McLean discovered that strains of antibiotic-resistant bacteria express hundreds of compounds not produced by their progenitors, many of which are potential secondary metabolites.

"It's as if the bacteria respond to the assault by the antibiotic with a 'save-all-ships' strategy of turning on hundreds of silent genes," said Bachmann, associate professor chemistry at Vanderbilt.

"This technique is something like fracking in the natural gas industry. We've known for a long time that there were large amounts of underground natural gas that we couldn't extract using conventional methods but now we can, using hydraulic fracturing technology. In a similar fashion we think we can use bacteria's antibiotic resistance to intensively mine the bacterial genome for new drug leads," he said.

The original purpose of the study was to take the most detailed look yet at what happens when microbes develop drug resistance. Bachmann is an expert in natural products drug discovery and McLean, an assistant professor of chemistry, is a pioneer in the development of analytical instrumentation and chemical techniques that can identify thousands of different biological compounds simultaneously, such as ion mobility-mass spectrometry.

"One of the daunting challenges is to rapidly inventory the tens to hundreds of thousands of molecules the bacteria construct to live, and then to read this inventory to understand how the bacteria compensate for their changing circumstances. To complicate matters further, we are looking for new drug-like molecules, so by definition we are looking for something that has not been seen before," said McLean.

Working with Research Assistant Dagmara Derewacz and graduate students Cody Goodwin and Ruth McNees, Bachmann and McLean started with the well-characterized soil bacterium Nocardiopsis. They exposed the bacterium to two different antibiotics -- streptomycin and rifampicin -- and observed the results.

"The first thing that happens is almost all of the bacteria die. Less than one cell in a million survives," said Bachmann.

The chemists then cultured the survivors (six streptomycin-resistant strains and five rifampicin-resistant strains) without the antibiotic and used McLean's instrumental methods to profile the drug-like compounds that they produced.

They discovered that the differences were much greater than they expected. The survivors had undergone extensive mutations, not only in the genes that produce secondary metabolites but also in the housekeeping genes that alter the way they make RNA and proteins. As a result, they determined that the resistant strains produced more than 300 compounds that were not expressed by the original organism.

"The cells appear to be 'de-repressing' as many of their silent genes as possible. This seems like a very drastic way to become drug resistant," Bachmann said.

McLean's team has developed strategies that allow them to automatically identify and compare the relative uniqueness and the relative abundance of tens of thousands of molecules from which the hundreds of novel compounds were found.

"What we are looking for are new species of molecules in the mutants that are the most unique and the most abundant," said Bachmann.

In the antibiotic-resistant Nocardiopsis strains the researchers found a total of five compounds that were both unique enough and abundant enough to isolate, determine their molecular structures and test for biological activity.

"Normally, we only find one compound per organism, so this is a significant improvement in yield, allowing us to get many new compounds from previously mined microorganisms," Bachmann said.

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 72

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Tigo's Guidance Gap Draws Lawsuit and Investor Scrutiny

Updated Category News Views 84

A Revenue Promise Hit the Wall Solar investing can turn ugly in a hurry when a supposedly near-term catalyst gets shoved down the calendar. That is the central bruise behind the securities class action involving Tigo Energy, not some arcane accounting footnote that only lawyers can love. The complaint alleges Tigo overstated the revenue contribution it expected from its...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 85

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 109

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 125

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Healthcare: ShiftMed Enhances Scheduling at UNC Health

Updated Category News Views 389

Introduction to ShiftMed Flex at UNC Health UNC Health is taking a significant step forward by implementing ShiftMed Flex, a transformative solution aimed at enhancing workforce efficiency throughout its network. This innovative AI-driven platform is designed to improve shift participation by better matching healthcare providers' schedules with available shifts,...

Continue Reading
Rivian's Q4 Financial Performance Sparks Investor Optimism

Updated Category News Views 168

Rivian's Strong Financial Performance Rivian Automotive stock has demonstrated significant resilience and growth recently. Investors are keen to understand the factors that are propelling RIVN stock upward. The latest quarterly earnings report has highlighted Rivian’s remarkable performance, which is robust evidence of the company's progress in the competitive electric...

Continue Reading
Purple Biotech's Innovative Advancements with CAPTN-3 Antibody Platform

Updated Category News Views 295

Exciting Developments in Cancer Treatment from Purple Biotech Purple Biotech, a clinical-stage company at the forefront of oncology, has made impressive strides in its novel tri-specific T cell and NK cell engager platform, known as CAPTN-3. This innovative approach demonstrates sustained tumor regression in an in-vivo model of triple-negative breast cancer and showcases...

Continue Reading
Raytron's Thermal Technology Enhances Robotaxi Safety in All Weather

Updated Category News Views 222

Raytron's Innovative Thermal Cameras for Autonomous Driving As advancements in technology reshape our transportation systems, one major player in the field is Raytron, a leader in infrared thermal imaging. A pressing challenge in the rollout of Level 4 (L4) robotaxis is ensuring safe operation in various climatic conditions, especially during extreme weather. With...

Continue Reading
Investors Urged to Join Centene Corporation Class Action Now

Updated Category News Views 116

Centene Corporation Faces Class Action Lawsuit Levi & Korsinsky, LLP has officially notified investors about a class action lawsuit targeting Centene Corporation. This lawsuit may affect shareholders who experienced losses due to alleged securities fraud. Centene Corporation, identified by its ticker CNC, is at the center of this legal action, which has drawn attention...

Continue Reading